FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 03/01/2023 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 03/01/2023 | S(1) | 5 | D | $758.2(2) | 19,242 | D | |||
Common Stock | 03/01/2023 | S(1) | 15 | D | $759.48(3) | 19,227 | D | |||
Common Stock | 03/01/2023 | S(1) | 10 | D | $760.54(4) | 19,217 | D | |||
Common Stock | 03/01/2023 | S(1) | 16 | D | $761.62(5) | 19,201 | D | |||
Common Stock | 03/01/2023 | S(1) | 9 | D | $762.28(6) | 19,192 | D | |||
Common Stock | 03/01/2023 | S(1) | 11 | D | $763.51(7) | 19,181 | D | |||
Common Stock | 03/01/2023 | S(1) | 17 | D | $764.49(8) | 19,164 | D | |||
Common Stock | 03/01/2023 | S(1) | 10 | D | $765.55(9) | 19,154 | D | |||
Common Stock | 03/01/2023 | S(1) | 7 | D | $766.32(10) | 19,147 | D |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
2. Represents volume-weighted average price of sales of 5 shares of Company stock on March 1, 2023 at prices ranging from $758.16 to $758.23. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2023 at each separate price. |
3. Represents volume-weighted average price of sales of 15 shares of Company stock on March 1, 2023 at prices ranging from $759.02 to $759.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2023 at each separate price. |
4. Represents volume-weighted average price of sales of 10 shares of Company stock on March 1, 2023 at prices ranging from $760.00 to $760.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2023 at each separate price. |
5. Represents volume-weighted average price of sales of 16 shares of Company stock on March 1, 2023 at prices ranging from $761.11 to $761.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2023 at each separate price. |
6. Represents volume-weighted average price of sales of 9 shares of Company stock on March 1, 2023 at prices ranging from $762.11 to $762.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2023 at each separate price. |
7. Represents volume-weighted average price of sales of 11 shares of Company stock on March 1, 2023 at prices ranging from $763.18 to $763.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2023 at each separate price. |
8. Represents volume-weighted average price of sales of 17 shares of Company stock on March 1, 2023 at prices ranging from $764.20 to $764.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2023 at each separate price. |
9. Represents volume-weighted average price of sales of 10 shares of Company stock on March 1, 2023 at prices ranging from $765.10 to $765.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2023 at each separate price. |
10. Represents volume-weighted average price of sales of 7 shares of Company stock on March 1, 2023 at prices ranging from $766.02 to $766.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2023 at each separate price. |
/s/**Arthur F. Ryan | 03/03/2023 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |